3-carbamoyl-1-[(2R,4S,5R)-5-[(hydrogen phosphonatooxy)(13C)methyl]-3,4-dihydroxy(2,3,4,5-13C4)oxolan-2-yl]-1λ5-pyridin-1-ylium

• ChemBase编号: 175099
• 分子式: C11H15N2O8P
• 平均质量: 339.18243519
• 单一同位素质量: 339.07337627
• SMILES: [n+]1(cc(ccc1)C(=O)N)[13C@H]1[13CH]([13C@@H]([13C@H](O1)[13CH2]OP(=O)([O-])O)O)O
• Canonical SMILES: O[13CH]1[13C@H](O)[13C@H](O[13C@H]1[n+]1cccc(c1)C(=O)N)[13CH2]OP(=O)(O)[O-]
• InChI: InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9?,11-/m1/s1/i5+1,7+1,8+1,9+1,11+1
• InChIKey: DAYLJWODMCOQEW-AZJCIWLKSA-N

名称和登记号

名称

• IUPAC标准名: 3-carbamoyl-1-[(2R,4S,5R)-5-[(hydrogen phosphonatooxy)(^1^3C)methyl]-3,4-dihydroxy(2,3,4,5-^1^3C₄)oxolan-2-yl]-1λ^5-pyridin-1-ylium
• IUPAC传统名: 3-carbamoyl-1-[(2R,4S,5R)-5-[(hydrogen phosphonatooxy)(^1^3C)methyl]-3,4-dihydroxy(2,3,4,5-^1^3C₄)oxolan-2-yl]-1λ^5-pyridin-1-ylium
• 别名: 3-(Aminocarbonyl)-1-(5-O-phosphono-β-D-ribofuranosyl)pyridinium-13C5 Inner Salt; 3-Carbamoyl-1-β-D-ribofuranosylpyridinium Hydroxide 5'-Phosphate-13C5 Inner Salt; NMN-13C5; Nicotinamide Mononucleotide-13C5; Nicotinamide Ribonucleoside 5'-Phosphate-13C5; Nicotinamide Ribonucleotide-13C5; Nicotinamide Ribotide-13C5; β-D-NMN-13C5; β-NMN-13C5; β-Nicotinamide Mononucleotide-13C5

登记号

• PubChem SID: 164231009
• PubChem CID: 71750999

理论计算性质

• Acid pKa: 1.2132069
• 质子受体: 7
• 质子供体: 4
• LogD (pH = 5.5): -7.492876
• LogD (pH = 7.4): -8.585161
• Log P: -6.244348
• 摩尔折射率: 70.5857 cm^3
• 极化性: 28.120956 Å^3
• 极化表面积: 166.25 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

详细说明

Toronto Research Chemicals - N407767

The labelled analogue of a product of the extracellular Nicotinamide phosphoribosyltransferase (eNAMPT) reaction and a key NAD+ intermediate. It ameliorates glucose intolerance by restoring NAD+ levels in HFD-induced T2D mice. It also enhances hepatic ins

参考文献

• Yoshino, J. et al.: Cell Metab., 14, 528 (2011)
• Caton, P.W. et al.: Diabetologia, 54, 3083 (2011)
• Formentini, L. et al.: BIochem. Pharmacol., 77, 1612 (2011)